Healthcare
Live Price
Offline$88.63
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars · Jun 23, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Menicon Co Ltd (MECNY) is a Healthcare stock with a market cap of $26.87B and listed on OTC. The stock last traded around $88.63 and up 0.0% across the available one-year price window (Jun 23, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +4.6%, EPS growth of +24.1%, a dividend yield of 0.0%. What stands out right now is revenue +4.6%, EPS +24.1%, free cash flow +62.6% with operating margin 20.3% and ROIC 4.3%. Valuation already assumes a fairly strong business story at P/E 11275.3 and price/sales 71.4. Stock Foundry combines MECNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
MECNY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
MECNY Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MECNY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$86.2B
-13.9% YoY
FY Net Income
$6.0B
-8.2% YoY
Free Cash Flow
-$1.2B
+61.4% YoY
Revenue Growth
+4.6%
EPS Growth
+24.1%
Gross Margin
52.7%
Net Margin
2.5%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 121.5B | 116.2B | 110.2B | 100.2B | 86.2B |
| Gross Profit | 65.1B | 61.0B | 58.5B | 52.9B | 45.8B |
| Operating Income | 10.1B | 9.0B | 12.1B | 10.0B | 8.1B |
| EBITDA | 18.5B | 15.6B | 19.3B | 17.5B | 14.6B |
| Net Income | 5.6B | 4.5B | 7.4B | 6.5B | 6.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.0B | 46.9B | 41.2B | 33.0B | 41.5B |
| Total Assets | 187.3B | 179.8B | 152.5B | 131.0B | 127.2B |
| Total Liabilities | 101.1B | 98.0B | 77.9B | 63.9B | 66.2B |
| Shareholder Equity | 86.1B | 81.7B | 74.6B | 67.0B | 60.9B |
| Total Debt | 75.1B | 70.8B | 53.6B | 42.4B | 45.3B |
| Net Debt | 33.0B | 23.9B | 12.3B | 9.4B | 3.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10.6B
-16.4% YoY
Capital Expenditures
11.9B
+25.5% YoY
Free Cash Flow
1.2B
+61.4% YoY
Key ratios
Gross Margin
52.7%
Operating Margin
20.3%
Net Margin
2.5%
ROE
2.3%
Debt / Equity
0.89x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.